Plasminogen Activator Inhibitor-1 Protects Mice Against Cardiac Fibrosis by Inhibiting Urokinase-type Plasminogen Activator-mediated Plasminogen Activation

Código QR

Plasminogen Activator Inhibitor-1 Protects Mice Against Cardiac Fibrosis by Inhibiting Urokinase-type Plasminogen Activator-mediated Plasminogen Activation

Abstract Plasminogen activator inhibitor-1 (PAI-1) is known to protect mice against cardiac fibrosis. It has been speculated that PAI-1 may regulate cardiac fibrosis by inactivating urokinase-type plasminogen activator (uPA) and ultimately plasmin (Pm) generation. However, the in vivo role of PAI-1...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kamlesh K. Gupta, Deborah L. Donahue, Mayra J. Sandoval-Cooper, Francis J. Castellino, Victoria A. Ploplis
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/b61808fa7a1343d587e54e6e25fbad0a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients
por: Yu Zuo, et al.
Publicado: (2021)

Discovery of a novel conformational equilibrium in urokinase-type plasminogen activator
por: Tobias Kromann-Hansen, et al.
Publicado: (2017)

Soluble urokinase plasminogen activator receptor as a marker for use of antidepressants.
por: Eva Haastrup, et al.
Publicado: (2014)

Preclinical evaluation of a urokinase plasminogen activator receptor-targeted nanoprobe in rhesus monkeys
por: Chen Y, et al.
Publicado: (2015)

PLASMINOGEN ACTIVATOR OF YERSINIA PESTIS
por: V. V. Evseeva, et al.
Publicado: (2015)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation
por: Line Jee Hartmann Rasmussen, et al.
Publicado: (2021)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) Independently Predicts Severity and Length of Hospitalisation in Patients With COVID-19
por: Helena Enocsson, et al.
Publicado: (2021)

Deep mutational scanning of the plasminogen activator inhibitor-1 functional landscape
por: Zachary M. Huttinger, et al.
Publicado: (2021)

Assessing plasminogen activation potential with global fibrinolytic assays
por: Tetsumei Urano, et al.
Publicado: (2020)

Recombinant tissue plasminogen activator in the treatment of suprachoroidal hemorrhage
por: Nancy Kunjukunju, et al.
Publicado: (2011)

Eleven genomic loci affect plasma levels of chronic inflammation marker soluble urokinase-type plasminogen activator receptor
por: Joseph Dowsett, et al.
Publicado: (2021)

Contribution of plasminogen activation towards the pathogenic potential of oral streptococci.
por: Andreas Itzek, et al.
Publicado: (2010)

Intra-Arterial Tissue Plasminogen Activator for Central Retinal Artery Occlusion
por: Sobol EK, et al.
Publicado: (2021)

Fibrinogen Activates the Capture of Human Plasminogen by Staphylococcal Fibronectin-Binding Proteins
por: Philippe Herman-Bausier, et al.
Publicado: (2017)

Soluble urokinase-type plasminogen activator receptor (suPAR) is a risk indicator for eGFR loss in kidney transplant recipients
por: Ulrich Jehn, et al.
Publicado: (2021)

Soluble urokinase plasminogen activator receptor (suPAR) predicts critical illness and kidney failure in patients admitted to the intensive care unit
por: Alexander C. Reisinger, et al.
Publicado: (2021)

Bioconjugation of recombinant tissue plasminogen activator to magnetic nanocarriers for targeted thrombolysis
por: Yang HW, et al.
Publicado: (2012)

Plasminogen activator inhibitor-1, free fatty acids, and insulin resistance in patients with myocardial infarction
por: Gruzdeva O, et al.
Publicado: (2013)

Unchanged plasma levels of the soluble urokinase plasminogen activator receptor in elective coronary artery bypass graft surgery patients and cardiopulmonary bypass use.
por: Waldemar Gozdzik, et al.
Publicado: (2014)

Soluble urokinase plasminogen activator receptor is associated with short-term mortality and enhanced reactive oxygen species production in acute-on-chronic liver failure
por: Yunyun Wang, et al.
Publicado: (2021)

Role of plasminogen activator inhibitor and free fatty acids in diagnosis of insulin resistance in patients with myocardial infarction
por: Olga Viktorovna Gruzdeva, et al.
Publicado: (2011)

Soluble urokinase plasminogen activator receptor in one-year prediction of major adverse cardiac events in patients after first myocardial infarction treated with primary percutaneous coronary intervention
por: Rafał N. Wlazeł, et al.
Publicado: (2018)

The plasminogen activation system modulates differently adipogenesis and myogenesis of embryonic stem cells.
por: Ola Hadadeh, et al.
Publicado: (2012)

Targeted delivery of tissue plasminogen activator by binding to silica-coated magnetic nanoparticle
por: Chen JP, et al.
Publicado: (2012)

Plasminogen Activating Inhibitor-1 Might Predict the Efficacy of Anti-PD1 Antibody in Advanced Melanoma Patients
por: Kentaro Ohuchi, et al.
Publicado: (2021)

Tissue plasminogen activator versus heparin for locking dialysis catheters: A systematic review
por: Belal M Firwana, et al.
Publicado: (2011)

Effect of Tissue Plasminogen Activator on Treatment Outcome and Neuronal Degeneration in Acute Ischemic Stroke
por: Muhammad Masoud, et al.
Publicado: (2021)

Extracellular matrix biomarker, fibulin-1, is closely related to NT-proBNP and soluble urokinase plasminogen activator receptor in patients with aortic valve stenosis (the SEAS study).
por: Ruan Kruger, et al.
Publicado: (2014)

Intravitreal Tissue Plasminogen Activator Injection for Treatment-Resistant Diabetic Macular Edema of the Vitrectomized Eye
por: Ren Aoki, et al.
Publicado: (2021)

Long non-coding RNA TRPM2-AS regulates microRNA miR-138-5p and PLAU (Plasminogen Activator, Urokinase) to promote the progression of gastric adenocarcinoma
por: Jun Sun, et al.
Publicado: (2021)

Association of plasminogen activator inhibitor-type 1 (-675 4G/5G) polymorphism with pre-eclampsia: systematic review.
por: Jessie A Morgan, et al.
Publicado: (2013)

The 4G/5G Polymorphism of Plasminogen Activator Inhibitor Type 1 is a Predictor of Moderate-to-Severe Thyroid Eye Disease
por: Katko M, et al.
Publicado: (2021)

Porphyromonas gingivalis Gingipains-Mediated Degradation of Plasminogen Activator Inhibitor-1 Leads to Delayed Wound Healing Responses in Human Endothelial Cells
por: Li-Ting Song, et al.
Publicado: (2021)

Plasminogen controls inflammation and pathogenesis of influenza virus infections via fibrinolysis.
por: Fatma Berri, et al.
Publicado: (2013)

Borrelia burgdorferi enolase is a surface-exposed plasminogen binding protein.
por: Angela M Floden, et al.
Publicado: (2011)

A suppressive effect of prostaglandin E2 on the expression of SERPINE1/plasminogen activator inhibitor-1 in human articular chondrocytes: An in vitro pilot study
por: Kayo Masuko, et al.
Publicado: (2009)

Tissue plasminogen activator is a ligand of cation-independent mannose 6-phosphate receptor and consists of glycoforms that contain mannose 6-phosphate
por: James J. Miller, et al.
Publicado: (2021)

Transconjunctival sutureless vitrectomy with tissue plasminogen activator, gas and intravitreal bevacizumab in the management of predominantly hemorrhagic age-related macular degeneration
por: Luis Arias, et al.
Publicado: (2010)

Long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal vein occlusion
por: Kumagai K, et al.
Publicado: (2019)

Tissue plasminogen activator (tPA) in the management of predominantly hemorrhagic age-related macular degeneration, milligram/milliliter or microgram/milliliter?
por: Boone NW, et al.
Publicado: (2012)